Marizyme, Inc. Share Price Other OTC
Equities
GBSX
US5703721028
Biotechnology & Medical Research
Sales 2021 | 210K 17.54M | Sales 2022 | 233K 19.48M | Capitalization | 21.28M 1.77B |
---|---|---|---|---|---|
Net income 2021 | -11M -918M | Net income 2022 | -38M -3.17B | EV / Sales 2021 | 329 x |
Net cash position 2021 | 2.12M 177M | Net Debt 2022 | 4.86M 405M | EV / Sales 2022 | 112 x |
P/E ratio 2021 |
-5.8
x | P/E ratio 2022 |
-0.56
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 67.69% |
Managers | Title | Age | Since |
---|---|---|---|
David Barthel
CEO | Chief Executive Officer | - | 16/21/16 |
George Kovalyov
DFI | Director of Finance/CFO | 39 | 21/21/21 |
Chairman | 70 | 22/21/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Stewart
BRD | Director/Board Member | 66 | 01/22/01 |
David Barthel
CEO | Chief Executive Officer | - | 16/21/16 |
William G. Hearl
BRD | Director/Board Member | 66 | 30/20/30 |
1st Jan change | Capi. | |
---|---|---|
-1.17% | 104B | |
+2.87% | 97.47B | |
+3.78% | 22.25B | |
-14.77% | 21.68B | |
-9.14% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |